ANNULÉ Jean-Emmanuel Sarry: Mitochondrial OxPHOS function and metabolic flexibility in drug resistance of acute myeloid leukemia
Organisateur : Alice Carrier
Lieu : ANNULÉ
Centre de Recherche en Cancérologie de Toulouse
Despite a high rate of complete remission after treatment with genotoxic agents, the prognosis is poor in human acute myeloid leukemia (AML), due to frequent relapses caused by resistant leukemic clones (RLCs). Our goal is to understand the causes of the drug resistance for the development of new treatments eradicating RLCs and overcoming patient relapses. Here we will discuss about the role of leukemic stem cells and mitochondria in drug resistance of AML.
Jean-Emmanuel Sarry is a Team Leader and a Principal Investigator in Hemato-Oncology at Inserm. Dr. Sarry received his PhD degree in Biochemistry from the University of Montpellier. He also completed his scientific training in Plant and Yeast Metabolism at the Department of Plant Physiology (CEA, Grenoble) and at the Department of Biology (University of Pennsylvania, Philadelphia), respectively. After studying the phenotypic heterogeneity of leukemic stem cells at University of Pennsylvania Medical School, he joined the Cancer Research Center of Toulouse in 2010. The major focus of his laboratory’s research is the role of oncometabolism and mitochondria in drug resistance of acute myeloid leukemia using a combination of biochemistry, omics approaches and innovative preclinical models.
1. Bosc C, Selak MA, SARRY JE. Resistance is futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment. CELL METABOLISM. 2017.
2. Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen B, Féliu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger M, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini B, Portais JC, Vergez F, Selak MA, Danet-Desnoyers G, Carroll MC, Récher C, SARRY JE. Chemotherapy resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. CANCER DISCOVERY. 2017.
3. Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, Riscal R, Yang G, Hirsch P, David M, De Mas-Mansat V, Delabesse E, Vallar L, Delhommeau F, Jouanin I, Ouerfelli O, Le Cam L, Linares LK, Junot C, Portais JC, Vergez F, Récher C, SARRY JE. Isocitrate dehydrogenase 1 mutations prime the all-trans-retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J EXP MED. 2016.
4. Scotland S., Saland E., Boutzen H., Senegas I., Peruga L., Peyraud R., Theodore F., Micklow E., Danet-Desnoyers G., Bono F., Manenti S., Levade T., Junot C., Portais JC., Alet N., Récher C., Selak MA., Carroll MC. SARRY JE. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. LEUKEMIA. 2013. 27(11): 2129-38